With any luck we might see some of these answers in the upcoming...

First 120 Last

Share
Profile

Follow
scarecrow

29 Posts.

20/04/21

12:05

Post #: 52589614
Share

Originally posted by amb005: ↑

Would have been good to know the amout of the harvest, to start to get an idea of revenue. Would like to know a few more things. Such as how many crops they can do a year, what kind of type they are growing, cause autoflowers they could do quicker and more than two a year.

So going by LGP figures, they say that 1000kg of dried flower converts to 100k 50 ml bottles of extracts, nice and simple calculation. So if the harvest they just sent to Extractas Bioscience was the 2000kg they had cultivating, means we will have 200k 50 ml bottles to sell, wonder what the wholesale price they get for this.

Would like to know when the Tasmanian commercial crop is planted, expected to be harvested, and how many crops can do a year.

A lot of questions that I hope we can get the answers for as think it will help the market in rerating, as of now we currently producing more than other companies, how much can this grow by considering how many crops we can do a year. Maybe thats one downside of the outdoor grows, might be restricted amount of crops a year, whereas indoor can keep it going despite the huge costs involved.

@plonka and @davefb , welcome aboard, good to see new investors finding out about ECS. Great time to be entering jealous my avaerage isnt at this price.

Expand

With any luck we might see some of these answers in the upcoming quarterly.

ECS Price at posting: 5.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

PL3

Patagonia looks to raise $2.15M for South American exploration and development

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

There are more pages in this discussion • 402 more messages in this thread...

First 120 Last

Add ECS (ASX) to my watchlist

(20min delay)
Last 1.8¢		Change 0.000(0.00%)		Mkt cap ! $23.19M

Open	High	Low	Value	Volume
1.8¢	1.8¢	1.8¢	$6.318K	351.0K

Buyers (Bids)

No.	Vol.	Price($)
6	2206000	1.7¢

Sellers (Offers)

Price($)	Vol.	No.
1.9¢	3101112	3

View Market Depth

No.	Vol.	Price($)
6	2206000	0.017
14	4100446	0.016
12	2650245	0.015
5	1132094	0.014
6	679561	0.013

Price($)	Vol.	No.
0.019	3101112	3
0.020	1445858	7
0.021	1222157	5
0.022	752190	5
0.023	735472	3

Last trade - 13.11pm 09/07/2024 (20 minute delay)

ECS (ASX) Chart

With any luck we might see some of these answers in the upcoming...

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

With any luck we might see some of these answers in the upcoming...

Top Stories

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News